RT Journal Article SR Electronic T1 Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 467 OP 474 DO 10.21873/invivo.12280 VO 35 IS 1 A1 YUSUKE TAKAYAMA A1 TAKASHI NAKAMURA A1 YUKI FUKUSHIRO A1 SHOHEI MISHIMA A1 KEN MASUDA A1 HIROYASU SHODA YR 2021 UL http://iv.iiarjournals.org/content/35/1/467.abstract AB Background/Aim: Chronic obstructive pulmonary disease coexisting with non-small-cell lung cancer (NSCLC) was reported to be associated with a longer progression-free survival (PFS) in patients treated with immune checkpoint inhibitors (ICIs). In the present study, we investigated the impact of emphysematous change on the treatment response to ICIs in patients with NSCLC. Patients and Methods: A total of 153 patients with advanced NSCLC who received ICIs (nivolumab, pembrolizumab, or atezolizumab) at our hospital from January 2016 to May 2019 were retrospectively enrolled. Results: According to the Goddard scoring system, 71 (46.4%) patients were classified as having emphysema and 82 (53.6%) as having no emphysema. Multivariate analysis showed that a good performance status and coexisting emphysema (hazard ratio=0.49; 95% confidence intervaI=0.28-0.84; p=0.010) were independent predictors of a better PFS. Conclusion: Recognizing emphysema coexisting with NSCLC may help predict the therapeutic efficacy of ICIs in such patients.